Literature DB >> 35789113

Skeletal Effects of Inducible ERα Deletion in Osteocytes in Adult Mice.

Madison L Doolittle1, Dominik Saul1, Japneet Kaur1, Jennifer L Rowsey1, Brittany Eckhardt1, Stephanie Vos1, Sarah Grain1, Kveta Kroupova1,2, Ming Ruan1, Megan Weivoda3, Merry Jo Oursler1, Joshua N Farr1, David G Monroe1, Sundeep Khosla1.   

Abstract

Estrogen is known to regulate bone metabolism in both women and men, but substantial gaps remain in our knowledge of estrogen and estrogen receptor alpha (ERα) regulation of adult bone metabolism. Studies using global ERα-knockout mice were confounded by high circulating sex-steroid levels, and osteocyte/osteoblast-specific ERα deletion may be confounded by ERα effects on growth versus the adult skeleton. Thus, we developed mice expressing the tamoxifen-inducible CreERT2 in osteocytes using the 8-kilobase (kb) Dmp1 promoter (Dmp1CreERT2 ). These mice were crossed with ERαfl//fl mice to create ERαΔOcy mice, permitting inducible osteocyte-specific ERα deletion in adulthood. After intermittent tamoxifen treatment of adult 4-month-old mice for 1 month, female, but not male, ERαΔOcy mice exhibited reduced spine bone volume fraction (BV/TV (-20.1%, p = 0.004) accompanied by decreased trabecular bone formation rate (-18.9%, p = 0.0496) and serum P1NP levels (-38.9%, p = 0.014). Periosteal (+65.6%, p = 0.004) and endocortical (+64.1%, p = 0.003) expansion were higher in ERαΔOcy mice compared to control (Dmp1CreERT2 ) mice at the tibial diaphysis, reflecting the known effects of estrogen to inhibit periosteal apposition and promote endocortical formation. Increases in Sost (2.1-fold, p = 0.001) messenger RNA (mRNA) levels were observed in trabecular bone at the spine in ERαΔOcy mice, consistent with previous reports that estrogen deficiency is associated with increased circulating sclerostin as well as bone SOST mRNA levels in humans. Further, the biological consequences of increased Sost expression were reflected in significant overall downregulation in panels of osteoblast and Wnt target genes in osteocyte-enriched bones from ERαΔOcy mice. These findings thus establish that osteocytic ERα is critical for estrogen action in female, but not male, adult bone metabolism. Moreover, the reduction in bone formation accompanied by increased Sost, decreased osteoblast, and decreased Wnt target gene expression in ERαΔOcy mice provides a direct link in vivo between ERα and Wnt signaling.
© 2022 American Society for Bone and Mineral Research (ASBMR). © 2022 American Society for Bone and Mineral Research (ASBMR).

Entities:  

Keywords:  ESTROGENS AND SERMs; GENETIC ANIMAL MODELS; OSTEOCYTES; OSTEOPOROSIS; SEX STEROIDS

Mesh:

Substances:

Year:  2022        PMID: 35789113      PMCID: PMC9474695          DOI: 10.1002/jbmr.4644

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.390


  57 in total

1.  Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women.

Authors:  Koji Fujita; Matthew M Roforth; Susan Demaray; Ulrike McGregor; Salman Kirmani; Louise K McCready; James M Peterson; Matthew T Drake; David G Monroe; Sundeep Khosla
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

2.  A shortened tamoxifen induction scheme to induce CreER recombinase without side effects on the male mouse skeleton.

Authors:  Ferran Jardí; Michaël R Laurent; Vanessa Dubois; Rougin Khalil; Ludo Deboel; Dieter Schollaert; Ludo Van Den Bosch; Brigitte Decallonne; Geert Carmeliet; Frank Claessens; Dirk Vanderschueren
Journal:  Mol Cell Endocrinol       Date:  2017-05-11       Impact factor: 4.102

3.  Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.

Authors:  Y E Chung; S H Lee; S-Y Lee; S-Y Kim; H-H Kim; F S Mirza; S-K Lee; J A Lorenzo; G S Kim; J-M Koh
Journal:  Osteoporos Int       Date:  2011-06-10       Impact factor: 4.507

4.  Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women.

Authors:  Pawel Szulc; Ego Seeman; François Duboeuf; Elisabeth Sornay-Rendu; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2006-12       Impact factor: 6.741

Review 5.  In vitro and in vivo approaches to study osteocyte biology.

Authors:  Ivo Kalajzic; Brya G Matthews; Elena Torreggiani; Marie A Harris; Paola Divieti Pajevic; Stephen E Harris
Journal:  Bone       Date:  2012-10-13       Impact factor: 4.398

6.  Identification of Senescent Cells in the Bone Microenvironment.

Authors:  Joshua N Farr; Daniel G Fraser; Haitao Wang; Katharina Jaehn; Mikolaj B Ogrodnik; Megan M Weivoda; Matthew T Drake; Tamara Tchkonia; Nathan K LeBrasseur; James L Kirkland; Lynda F Bonewald; Robert J Pignolo; David G Monroe; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2016-10-24       Impact factor: 6.741

7.  Bone mass, bone strength, and their relationship in developing CD-1 mice.

Authors:  Wendy E Ward; Ana V Piekarz; Debbie Fonseca
Journal:  Can J Physiol Pharmacol       Date:  2007-02       Impact factor: 2.273

8.  Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels.

Authors:  Sandra Jastrzebski; Judith Kalinowski; Marina Stolina; Faryal Mirza; Elena Torreggiani; Ivo Kalajzic; Hee Yeon Won; Sun-Kyeong Lee; Joseph Lorenzo
Journal:  J Bone Miner Res       Date:  2013-03       Impact factor: 6.741

9.  Deletion of Estrogen Receptor Beta in Osteoprogenitor Cells Increases Trabecular but Not Cortical Bone Mass in Female Mice.

Authors:  Kristy M Nicks; Koji Fujita; Daniel Fraser; Ulrike McGregor; Matthew T Drake; Meghan E McGee-Lawrence; Jennifer J Westendorf; David G Monroe; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2015-10-13       Impact factor: 6.741

10.  Missense Mutations in LRP5 Associated with High Bone Mass Protect the Mouse Skeleton from Disuse- and Ovariectomy-Induced Osteopenia.

Authors:  Paul J Niziolek; Whitney Bullock; Matthew L Warman; Alexander G Robling
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.